查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2030 年神經免疫藥物市場預測：按產品類型、適應症和地區分類的全球分析
市場調查報告書
商品編碼
1383453

2030 年神經免疫藥物市場預測：按產品類型、適應症和地區分類的全球分析

Neuroimmunology Drugs Market Forecasts to 2030 - Global Analysis By Product Type (Monoclonal Antibodies, Small Molecules, Recombinant Protein, Cytokines, Lymphocytes and Other Product Types), Indication and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球神經免疫藥物市場規模為 238.7 億美元，預計在預測期內將以 9.5% 的年複合成長率成長，到 2030 年達到 450.5 億美元。

神經免疫藥物市場專注於治療涉及神經和免疫系統的疾病。這包括影響神經系統的疾病，例如視神經脊髓炎 (NMO)、多發性硬化症 (MS) 和其他自體免疫疾病。該領域的許多神經系統疾病都屬於自體自體免疫疾病的範疇，其中免疫系統會錯誤識別並攻擊神經系統成分，例如多發性硬化症（MS）中的髓鞘。

神經免疫疾病的發生率增加

隨著越來越多的人被診斷出患有神經免疫疾病，需要治療的患者數量也會增加，增加了對神經免疫治療的需求。隨著這些病理數量的增加，尋找更有效治療方法的研究和開發配合措施也不斷增加。製藥公司正在投入資源開發新藥，以滿足不斷增加的患者需求。新藥的開發是為了滿足更多患者群體和改善治療結果的需求。科學家和製藥公司正在研究新策略和前沿藥物治療前景。

開發成本高

研發投資可能會受到高昂的開發成本的限制，這使得新興企業在財務上難以推出和維持開發神經免疫疾病療法的計劃。我不知道。為了收回開發成本並產生利潤，神經免疫藥物公司可能會收取溢價。因此，過高的藥品價格會限制患者的取得和負擔能力，並降低治療效果。

創新藥物研發

隨著科學進步，新的藥物標靶、途徑和可能的治療方法不斷被發現。這將鼓勵開發神經免疫疾病的新藥和治療方法。改進研究可以促進學術機構、研究小組和製藥公司之間的合作。此外，這些小組的努力加速了知識交流和研究與開發，確定了與神經免疫疾病相關的特定細胞和分子靶標，並推進了研究。因此，針對各種疾病的根本原因並改變免疫反應的特異性治療方法正在開發中。

激烈的競爭

當公司降低藥品價格以獲取或維持市場佔有率時，過度的市場競爭會對定價造成壓力。這可能會影響藥物研究的盈利，儘管它可以透過節省資金來幫助患者。藥物的研究和核准過程可能會倉促，以幫助製藥公司保持競爭力，引發對其有效性和安全性的質疑。這不僅會危及病人安全，還會危及產業信任。為了減少市場競爭的負面影響，重要的是要專注於治療進展，同時保持法規監督、品質基準和嚴格的研發標準。

COVID-19 的影響

封鎖和其他限制延遲或阻止了一些研究活動，包括臨床試驗和實驗室研究。這推遲了正在進行的神經免疫藥物舉措的開發。一些製藥公司可能已將重點從神經免疫學藥物開發轉移，轉而將研究工作和資源集中在與 COVID-19 相關的治療和疫苗上。因此，可能會出現藥品短缺或生產延誤，這對市場成長產生負面影響。

單株抗體領域預計將成為預測期內最大的市場

由於單株抗體經常被用作包括多發性硬化症 (MS) 和視神經脊髓炎 (NMO) 在內的神經免疫疾病的疾病緩解疾病療法，因此單株抗體領域預計將經歷良好的成長。為了減少發炎和抑制發炎反應，這些單株抗體可能能夠減緩疾病進程並避免復發。發炎是許多神經免疫疾病的主要因素，單株抗體可以減輕發炎、緩解不適並阻止神經組織損傷。某些單株抗體的作用是防止自體自體免疫系統攻擊髓鞘等神經系統成分，有助於防止神經系統受到傷害。

多發性硬化症領域預計在預測期內具有最高的年複合成長率

預計多發性硬化症領域在預測期內將呈現最高的年複合成長率。這是因為多發性硬化症（MS）是神經免疫療法市場上最常見的神經系統疾病之一。在多發性硬化症（MS）這種自體免疫疾病中，免疫系統錯誤地攻擊中樞神經系統（CNS）神經纖維周圍的保護性髓磷脂層。這種疾病會引起許多神經系統症狀。此外，由於正在進行的研究，正在開發新的治療方法，並且正在重新調整現有藥物來治療多發性硬化症。因此，這些最先進治療的目標是更好的結果和更多的治療選擇。

佔比最大的地區：

由於多發性硬化症、視神經脊髓炎和其他自體自體免疫神經系統疾病等神經免疫疾病在該地區變得越來越普遍，預計亞太地區將在預測期內佔據最大的市場佔有率。由於治療方案的改進、早期診斷以及對神經免疫疾病的認知提高，確切的盛行率因國家和地區而異。許多地方政府正在改善神經免疫疾病的管理。這包括資助研究、擴大醫療保健基礎設施以及鼓勵早期發現和早期療育。

複合年複合成長率最高的地區：

預計北美在預測期內的年複合成長率最高。這是因為許多神經免疫學相關藥物的臨床試驗都是在北美進行的。北美因其強大的醫療保健系統、研究機構和多樣化的患者基礎而成為進行臨床研究的理想地點。美國食品藥物管理局（FDA）和加拿大衛生署是兩個法規機構，負責確保神經免疫學相關藥物的安全性和有效性，並為藥物核准建立既定的法規結構。在北美，許多患者都有健康保險，這可以減少自付費用並改善獲得神經免疫治療的機會。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 利害關係人
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球神經免疫藥物市場：依產品類型

  • 單株抗體
  • 低分子
  • 重組蛋白
  • 細胞因子
  • 淋巴球
  • 其他產品類型

第6章 全球神經免疫藥物市場：依適應症分類

  • 多發性硬化症
  • 阿茲海默症
  • 帕金森氏症
  • 重症肌無力
  • 格林-巴利症候群
  • 視神經脊髓炎譜系障礙
  • 肌萎縮側索硬化症
  • 慢性發炎去髓鞘化神經病變
  • 其他適應症

第7章 全球神經免疫藥物市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第8章 進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第9章 公司簡介

  • Biogen
  • Hoffmann-La Roche Ltd
  • T3D Therapeutics
  • Novartis AG
  • Celgene Corp
  • Merck KGaA
  • Johnson & Johnson
  • Eisai Co Ltd
  • Sanofi
  • Actelion Pharmaceuticals Ltd.
  • ImmunoBrain Checkpoint
  • Lundbeck
  • Eli Lilly
  • AstraZeneca
  • UCB SA
  • AB Science SA
  • AstronauTx
  • Genetech Inc
  • Inflammasome Therapeutics
  • TauRX Therapeutics Ltd
Product Code: SMRC24301

According to Stratistics MRC, the Global Neuroimmunology Drugs Market is accounted for $23.87 billion in 2023 and is expected to reach $45.05 billion by 2030 growing at a CAGR of 9.5% during the forecast period. The market for neuroimmunology drugs is mostly focused on the treatment of illnesses involving the neurological and immune systems. This covers conditions that affect the neurological system, such as neuromyelitis optica (NMO), multiple sclerosis (MS), and other autoimmune illnesses. Many of the neurological disorders in this area fall within the category of autoimmune illnesses, in which the immune system misidentifies and attacks nervous system components, including the myelin sheath in multiple sclerosis (MS).

Market Dynamics:

Driver:

Increasing incidence of neuroimmunological disorders

As more people receive diagnoses for neuroimmunological illnesses, there will be a greater number of patients in need of care thus the need for neuroimmunology medications is fueled by this. Increased efforts are being made in research and development to identify more effective therapies as a result of the rising occurrence of these conditions. Pharmaceutical corporations allocate resources towards the creation of novel medications to cater to the growing number of patients. The creation of novel medicines is aided by the requirement to serve a wider patient population and to enhance treatment outcomes; scientists and pharmaceutical companies investigate fresh strategies and cutting-edge medication prospects.

Restraint:

High development costs

Research & development investment may be discouraged by high development costs and it may be financially difficult for startups and smaller pharmaceutical companies to launch or maintain medication development projects for neuroimmunological illnesses. In order to recover development expenses and generate a profit, neuroimmunology pharmaceutical companies could set their prices at premium levels. Thus, the excessive medicine costs may make treatment less effective by limiting patient access and affordability.

Opportunity:

Innovative drug developments

New drug targets, routes, and possible treatments are found as a result of scientific advances. This motivates the creation of novel medications and therapeutic modalities for neuroimmunological illnesses. Research improvements enable collaboration among academic institutions, research groups, and pharmaceutical businesses. Moreover, the knowledge exchange and medication development are accelerated by this group effort and research progresses in identifying certain cellular and molecular targets linked to neuroimmunological diseases. As a result, specific treatments that target the underlying causes of various illnesses and modify the immune response are developed.

Threat:

Intense rivalry

Competition that is too fierce might put pressure on pricing because businesses would drop the price of their drugs to get or keep market share. This may have an effect on the profitability of medication research, even while it can help patients by saving money. Drug research and approval processes may be hurried by pharmaceutical corporations in an effort to stay competitive, raising questions about their efficacy and safety. Patient safety as well as industry confidence may be jeopardized by this. To mitigate the possible adverse consequences of market competition, regulatory supervision, quality benchmarks, and a dedication to therapeutic advancement while upholding rigorous R&D standards are crucial.

COVID-19 Impact

Lockdowns and other limitations caused several research activities including clinical trials and laboratory research to be postponed or hindered. This slowed down the development of on-going neuroimmunology medication initiatives. Some pharmaceutical firms may have changed their focus away from developing drugs for neuroimmunology and instead concentrated their research efforts and resources toward COVID-19-related therapies and vaccines. This resulted in possible shortages and production delays of pharmaceuticals thus negatively impacted the market growth.

The monoclonal antibodies segment is expected to be the largest during the forecast period

The monoclonal antibodies segment is estimated to have a lucrative growth, as these disease modifying treatments for neuroimmunological conditions including multiple sclerosis (MS) and neuromyelitis optica (NMO), monoclonal antibodies are frequently used. With the goal of lowering inflammation and suppressing the inflammatory response, these mAbs may be able to delay the course of the illness and avoid relapses. A major factor in many neuroimmunological illnesses is inflammation and inflammation can be lessened by monoclonal antibodies, which can aid with discomfort relief and stop more nerve tissue damage. Certain mAbs function by preventing the autoimmune system from attacking nervous system elements like the myelin sheath thus they aid in preventing harm to the neurological system by doing this.

The multiple sclerosis segment is expected to have the highest CAGR during the forecast period

The multiple sclerosis segment is anticipated to witness the highest CAGR growth during the forecast period, as it is one of the most common neurological disorders in the market for neuroimmunology medications is multiple sclerosis (MS). The protective myelin layer that envelops nerve fibres in the central nervous system (CNS) is wrongly attacked by the immune system in multiple sclerosis (MS), an autoimmune illness. Numerous neurological symptoms are caused by this illness. Moreover novel treatments are being developed and current medications are being repurposed for the treatment of multiple sclerosis as a result of on-going research thus the goals of these cutting-edge treatments are better results and more treatment alternatives.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to neuroimmunological diseases like multiple sclerosis, neuromyelitis optica, and other autoimmune nervous system illnesses have become more common in the Asia-Pacific area. Each nation and area has a different precise prevalence as a result of improved treatment options, early diagnosis, and growing awareness of neuroimmunological illnesses. The management of neuroimmunological illnesses is being improved by a number of regional governments. This entails providing money for research, expanding the infrastructure for healthcare, and encouraging early detection and intervention.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period; owing to the clinical trials for medications linked to neuroimmunology which are mostly conducted in North America. It's a desirable place to do clinical research because of its strong healthcare system, research institutes, and varied patient base. The U.S. Food and Drug Administration (FDA) and Health Canada are two regulatory bodies that guarantee the safety and effectiveness of neuroimmunology medications, creating a well-established regulatory framework for drug approval. In North America, a large number of patients have health insurance, which can help to lower out-of-pocket treatment expenses and improve access to neuroimmunology medications.

Key players in the market

Some of the key players profiled in the Neuroimmunology Drugs Market include: Biogen, Hoffmann-La Roche Ltd, T3D Therapeutics, Novartis AG, Celgene Corp, Merck KGaA, Johnson & Johnson, Eisai Co Ltd, Sanofi, Actelion Pharmaceuticals Ltd., ImmunoBrain Checkpoint, Lundbeck, Eli Lilly, AstraZeneca, UCB SA, AB Science S.A., AstronauTx, Genetech Inc, Inflammasome Therapeutics and TauRX Therapeutics Ltd

Key Developments:

In September 2023, Biogen Inc has completed the acquisition of Reata Pharmaceuticals, Inc. a company focused on developing therapeutics that regulates cellular metabolism and inflammation in serious neurologic diseases.

In June 2023, Roche announced that they had entered into a definitive agreement to acquire Telavant Holdings, Inc. (Telavant), a Roivant company, owned by Roivant Sciences Ltd. and Pfizer Inc. The agreement includes the development, manufacturing and commercialisation rights in the US and Japan for Telavant's RVT-3101.

In April 2023, T3D Therapeutics, Inc. a clinical stage drug development company engaged in the development of T3D-959, a new orally administered treatment for Alzheimer's disease (AD), announced the initiation of dosing in a Phase 2 clinical study of neurometabolic regulator

Product Types Covered:

  • Monoclonal Antibodies
  • Small Molecules
  • Recombinant Protein
  • Cytokines
  • Lymphocytes
  • Other Product Types

Indications Covered:

  • Multiple Sclerosis
  • Alzheimer's Disease
  • Parkinson's Disease
  • Myasthenia Gravis
  • Guillain-Barre Syndrome
  • Neuromyelitis Optica Spectrum Disorder
  • Amyotrophic Lateral Sclerosis
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • Other Indications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Neuroimmunology Drugs Market, By Product Type

  • 5.1 Introduction
  • 5.2 Monoclonal Antibodies
  • 5.3 Small Molecules
  • 5.4 Recombinant Protein
  • 5.5 Cytokines
  • 5.6 Lymphocytes
  • 5.7 Other Product Types

6 Global Neuroimmunology Drugs Market, By Indication

  • 6.1 Introduction
  • 6.2 Multiple Sclerosis
  • 6.3 Alzheimer's Disease
  • 6.4 Parkinson's Disease
  • 6.5 Myasthenia Gravis
  • 6.6 Guillain-Barre Syndrome
  • 6.7 Neuromyelitis Optica Spectrum Disorder
  • 6.8 Amyotrophic Lateral Sclerosis
  • 6.9 Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • 6.10 Other Indications

7 Global Neuroimmunology Drugs Market, By Geography

  • 7.1 Introduction
  • 7.2 North America
    • 7.2.1 US
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 UK
    • 7.3.3 Italy
    • 7.3.4 France
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 Japan
    • 7.4.2 China
    • 7.4.3 India
    • 7.4.4 Australia
    • 7.4.5 New Zealand
    • 7.4.6 South Korea
    • 7.4.7 Rest of Asia Pacific
  • 7.5 South America
    • 7.5.1 Argentina
    • 7.5.2 Brazil
    • 7.5.3 Chile
    • 7.5.4 Rest of South America
  • 7.6 Middle East & Africa
    • 7.6.1 Saudi Arabia
    • 7.6.2 UAE
    • 7.6.3 Qatar
    • 7.6.4 South Africa
    • 7.6.5 Rest of Middle East & Africa

8 Key Developments

  • 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 8.2 Acquisitions & Mergers
  • 8.3 New Product Launch
  • 8.4 Expansions
  • 8.5 Other Key Strategies

9 Company Profiling

  • 9.1 Biogen
  • 9.2 Hoffmann-La Roche Ltd
  • 9.3 T3D Therapeutics
  • 9.4 Novartis AG
  • 9.5 Celgene Corp
  • 9.6 Merck KGaA
  • 9.7 Johnson & Johnson
  • 9.8 Eisai Co Ltd
  • 9.9 Sanofi
  • 9.10 Actelion Pharmaceuticals Ltd.
  • 9.11 ImmunoBrain Checkpoint
  • 9.12 Lundbeck
  • 9.13 Eli Lilly
  • 9.14 AstraZeneca
  • 9.15 UCB SA
  • 9.16 AB Science S.A.
  • 9.17 AstronauTx
  • 9.18 Genetech Inc
  • 9.19 Inflammasome Therapeutics
  • 9.20 TauRX Therapeutics Ltd

List of Tables

  • Table 1 Global Neuroimmunology Drugs Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 4 Global Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
  • Table 5 Global Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
  • Table 6 Global Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
  • Table 7 Global Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
  • Table 8 Global Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 9 Global Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
  • Table 10 Global Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 11 Global Neuroimmunology Drugs Market Outlook, By Alzheimer's Disease (2021-2030) ($MN)
  • Table 12 Global Neuroimmunology Drugs Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
  • Table 13 Global Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
  • Table 14 Global Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
  • Table 15 Global Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
  • Table 16 Global Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
  • Table 17 Global Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
  • Table 18 Global Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 19 North America Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 20 North America Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 21 North America Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 22 North America Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
  • Table 23 North America Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
  • Table 24 North America Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
  • Table 25 North America Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
  • Table 26 North America Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 27 North America Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
  • Table 28 North America Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 29 North America Neuroimmunology Drugs Market Outlook, By Alzheimer's Disease (2021-2030) ($MN)
  • Table 30 North America Neuroimmunology Drugs Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
  • Table 31 North America Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
  • Table 32 North America Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
  • Table 33 North America Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
  • Table 34 North America Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
  • Table 35 North America Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
  • Table 36 North America Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 37 Europe Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 38 Europe Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 39 Europe Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 40 Europe Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
  • Table 41 Europe Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
  • Table 42 Europe Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
  • Table 43 Europe Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
  • Table 44 Europe Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 45 Europe Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
  • Table 46 Europe Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 47 Europe Neuroimmunology Drugs Market Outlook, By Alzheimer's Disease (2021-2030) ($MN)
  • Table 48 Europe Neuroimmunology Drugs Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
  • Table 49 Europe Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
  • Table 50 Europe Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
  • Table 51 Europe Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
  • Table 52 Europe Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
  • Table 53 Europe Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
  • Table 54 Europe Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 55 Asia Pacific Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 56 Asia Pacific Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 57 Asia Pacific Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 58 Asia Pacific Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
  • Table 59 Asia Pacific Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
  • Table 60 Asia Pacific Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
  • Table 61 Asia Pacific Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
  • Table 62 Asia Pacific Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 63 Asia Pacific Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
  • Table 64 Asia Pacific Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 65 Asia Pacific Neuroimmunology Drugs Market Outlook, By Alzheimer's Disease (2021-2030) ($MN)
  • Table 66 Asia Pacific Neuroimmunology Drugs Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
  • Table 67 Asia Pacific Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
  • Table 68 Asia Pacific Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
  • Table 69 Asia Pacific Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
  • Table 70 Asia Pacific Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
  • Table 71 Asia Pacific Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
  • Table 72 Asia Pacific Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 73 South America Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 74 South America Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 75 South America Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 76 South America Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
  • Table 77 South America Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
  • Table 78 South America Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
  • Table 79 South America Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
  • Table 80 South America Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 81 South America Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
  • Table 82 South America Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 83 South America Neuroimmunology Drugs Market Outlook, By Alzheimer's Disease (2021-2030) ($MN)
  • Table 84 South America Neuroimmunology Drugs Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
  • Table 85 South America Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
  • Table 86 South America Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
  • Table 87 South America Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
  • Table 88 South America Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
  • Table 89 South America Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
  • Table 90 South America Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 91 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Country (2021-2030) ($MN)
  • Table 92 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 93 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
  • Table 94 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Small Molecules (2021-2030) ($MN)
  • Table 95 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Recombinant Protein (2021-2030) ($MN)
  • Table 96 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Cytokines (2021-2030) ($MN)
  • Table 97 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Lymphocytes (2021-2030) ($MN)
  • Table 98 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 99 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Indication (2021-2030) ($MN)
  • Table 100 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Multiple Sclerosis (2021-2030) ($MN)
  • Table 101 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Alzheimer's Disease (2021-2030) ($MN)
  • Table 102 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Parkinson's Disease (2021-2030) ($MN)
  • Table 103 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Myasthenia Gravis (2021-2030) ($MN)
  • Table 104 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Guillain-Barre Syndrome (2021-2030) ($MN)
  • Table 105 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Neuromyelitis Optica Spectrum Disorder (2021-2030) ($MN)
  • Table 106 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Amyotrophic Lateral Sclerosis (2021-2030) ($MN)
  • Table 107 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Chronic Inflammatory Demyelinating Polyradiculoneuropathy (2021-2030) ($MN)
  • Table 108 Middle East & Africa Neuroimmunology Drugs Market Outlook, By Other Indications (2021-2030) ($MN)